HC Wainwright Reiterates Buy Rating on SAB Biotherapeutics
HC Wainwright maintains its positive outlook on SAB Biotherapeutics with a $10 price target, a 159.07% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on SAB Biotherapeutics, Inc. (SABS) on June 15, 2026, with a price target of $10.
- HC Wainwright's $10 price target implies 159.07% upside from SAB Biotherapeutics, Inc.'s ($SABS) current $3.86 share price.
- Shares of SAB Biotherapeutics are trading around $3.33, with a market cap of about $298.2 million and a 52-week range between $1.65 and $6.60.
- Institutional activity includes Perceptive Advisors adding 5,628,533 shares, now holding 6,431,743 shares valued at $24.6 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, HC Wainwright reiterated its buy rating on SAB Biotherapeutics, Inc. (NasdaqCM: SABS), maintaining a price target of $10. This comes as shares of the biotechnology company are trading around $3.33.
SAB Biotherapeutics, Inc. Stock Up 1.8%
Shares of NasdaqCM:SABS traded near $3.33 recently. SAB Biotherapeutics has a market cap of approximately $298.2 million. The stock has seen a 52-week low of $1.65 and a high of $6.60. Its 50-day moving average is $3.69, while the 200-day moving average is $3.48. The company has a strong liquidity position with a current ratio of 11.45 and a quick ratio of 11.06, although it carries some leverage with a debt-to-equity ratio of 2.72.
$SABS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 15, 2026, HC Wainwright & Co. reiterated its buy rating on SAB Biotherapeutics with a $10 price target. On the same day, Leerink Partners maintained their buy rating with a $12 target. Earlier, on May 22, 2026, Citigroup initiated coverage with a buy rating and an $11 target, while Jefferies did the same on May 20, 2026, also with an $11 target. The consensus among analysts is a strong buy, with a mean price target of $10.6 based on 10 opinions.
Other Institutional Activity in SAB Biotherapeutics
Among institutional investors, Perceptive Advisors LLC significantly increased its position by adding 5,628,533 shares, bringing its total to 6,431,743 shares valued at about $24.6 million. Similarly, Balyasny Asset Management L.P. boosted its holdings by 3,285,000 shares, now holding 3,760,439 shares worth roughly $14.4 million. Meanwhile, VIVO Capital, LLC maintained its position with 11,420,000 shares valued at approximately $43.7 million.
Insider Buying and Selling at SAB Biotherapeutics, Inc.
Recent insider activity includes several notable transactions. On February 3, 2026, CEO Samuel Reich acquired 4,800,000 shares, while Chief Financial Officer Lucy To bought 2,400,000 shares. Chief Operating Officer Christoph Lawrence Bausch and Chief Medical Officer Alexandra Kropotova each purchased 1,800,000 and 2,400,000 shares, respectively. These transactions were not part of a pre-planned trading program.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company based in Miami Beach, Florida. It focuses on developing human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. Its lead product candidate, SAB-142, is in Phase 2b clinical trials for treating autoimmune type 1 diabetes. Founded in 2014, the company is led by CEO Samuel J. Reich and has about 86 employees.
Bottom Line
SAB Biotherapeutics continues to attract attention from analysts and institutional investors. HC Wainwright's reiterated buy rating and $10 price target underscore confidence in the company's prospects. Investors will be watching for upcoming developments, particularly as SAB advances its clinical trials. As always, remember that this analysis is based on past data and should not be construed as current investment advice.
Get SAB Biotherapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SABS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.